Kyowa Hakko Kirin Returns Rights To Busulfex To Otsuka Pharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin returns rights to hematopoietic stem cell transplant therapy drug Busulfex in Japan and six Asian regions to Otsuka Pharmaceuticals, the companies announced Sept. 14